Sanguine's Budgets Are Now in Place to Plan FDA Testing of PHER-O2.

PASADENA, Calif. -- Sanguine Corp. (OTC Bulletin Board: SGNC), a bio-pharmaceutical company focused on the development of an oxygen-carrying synthetic substitute for human red blood cells, announced its budgets are now in place to plan FDA testing and to select a manufacturer of PHER-O2 in early 2005.

The company will convene a meeting in January of its Medical Advisory Board to finalize the details. Presentations will be made by Sanguine's regulatory affairs consultants and by the company's recent Medical Board addition, Dr. Robert Kwun. The presentations will detail the protocol planning for an FDA indication for retinal surgery and for a yet unnamed second indication. The approach will be to demonstrate the safety and efficacy of PHER-O2 for both procedures.

Additionally, the company is in discussions with a company to manufacture PHER-O2. The intent will be to manufacture PHER-O2 for pre-clinical sales to universities and others in 2005. Several groups desirous of using PHER-O2 in multiple areas have contacted the company. Additional information relating to the manufacture and sales of PHER-O2 will be released, as they become available.

Thomas Drees, Ph.D., chairman and CEO of Sanguine Corp., stated, "We are excited to commence our FDA trial work in the near future. We are also pleased to be able to offer for sale PHER-O2 to companies who are interested in its oxygen-carrying properties, where FDA approval is not necessary. Now that our budgets are in place, and with the ability to define a manufacturer, we look forward to 2005 and an opportunity year for Sanguine."

Sanguine Corp. is a development-stage company focused on the research and development of PHER-O2, a synthetic red blood cell product with potential applications in a variety of specialties, including: transfusions, CAT scans, cardioplegia and the treatment of heart attacks, strokes, head and neck tumors and hemorrhagic shock. The company is also developing non-medical applications for its perfluorocarbon (PFC) product.

For information related to the Sanguine Corp., contact: Investor Relations: Michael Dancy, 801-746-3570, e-mail: [e-mail], or visit: www.sanguine-corp.com.

Forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including without limitation, continued acceptance of the company's products, increased levels of competition for the company, new products and technological changes, the company's dependence on third-party suppliers, and other risks detailed from time to time in the company's periodic reports filed with the Securities and Exchange Commission.